Drug Trial Radar · NCT06576271
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
143
Actual
Start
Sep 2, 2024
Primary completion
Feb 1, 2028
Study completion Feb 1, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung disease associated with connective tissue disease (Part D)
Conditions
- Systemic Lupus Erythematosus
Interventions
GSK4527363Drug
GSK4527363 will be administered to participants.
Placebo matching GSK4527363Drug
Placebo matching GSK4527363 will be administered to participants.
BelimumabDrug
Belimumab will be administered to participants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and C: Number of Participants with Non-serious Adverse Events and Serious Adverse EventsTime frame: Up to Week 52
- Parts B and D: Number of Participants with Non-serious Adverse Events and Serious Adverse EventsTime frame: Up to Week 68
- Parts A and C: Number of Participants with Clinically Significant Changes in Physical Examination, Laboratory Parameters, Vital Signs, and 12 lead Electrocardiogram (ECG) FindingsTime frame: Up to Week 52
- Parts B and D: Number of Participants with Clinically Significant Changes in Physical Examination, Laboratory Parameters, Vital Signs, and 12 lead Electrocardiogram (ECG) FindingsTime frame: Up to Week 68
- Parts A and C: Number of Participants with Clinically Significant Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Week 52
- Parts B, and D: Number of Participants with Clinically Significant Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Week 68
Locations
23 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Rosario, Argentina
GSK Investigational Site
San Juan Bautista, Argentina
GSK Investigational Site
San Miguel de Tucumán, Argentina
GSK Investigational Site
Juiz de Fora, Brazil
GSK Investigational Site
Porto Alegre, Brazil
GSK Investigational Site
Salvador, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Bydgoszcz, Poland
GSK Investigational Site
Poznan, Poland
GSK Investigational Site
Warsaw, Poland
GSK Investigational Site
Wroclaw, Poland
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Bilbao, Spain
GSK Investigational Site
Sabadell Barcelona, Spain
GSK Investigational Site
Valladolid, Spain
GSK Investigational Site
Pamplona Iruna, Navarre, Spain
GSK Investigational Site
Cambridge, United Kingdom
GSK Investigational Site
Liverpool, United Kingdom
GSK Investigational Site
London, United Kingdom
GSK Investigational Site
Middlesex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.